UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2008
SCHERING-PLOUGH CORPORATION
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
New Jersey
(State or Other Jurisdiction of
Incorporation)
|
|
1-6571
(Commission File Number)
|
|
22-1918501
(IRS Employer
Identification Number) |
2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (908) 298-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
Schering-Plough today issued a press release titled “Schering-Plough Reports Financial Results for
Second Quarter of 2008” and provided additional supplemental financial data. The press release is
furnished as Exhibit 99.1 to this 8-K. The supplemental financial data is furnished as Exhibit
99.2 to this 8-K.
ITEM 8.01 OTHER EVENTS
Terje R. Pedersen, M.D., Professor of Medicine, the lead independent
investigator in the SEAS study, today issued a press release titled “Results
from the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study.” The SEAS
study investigated the effects of intensive cholesterol lowering with the
combination of simvastatin and ezetimibe (marketed as VYTORIN by the
Merck/Schering-Plough joint venture) in patients with aortic stenosis. This
press release is furnished as Exhibit 99.3 to this 8-K.
The University of Oxford Clinical Trial Service Unit and Epidemiological
Studies Unit (CTSU) today issued a press release titled “Independent Analyses
of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe.” CTSU conducted and
interpreted an independent analysis of data in the SEAS study, the SHARP (Study
of Heart and Renal Protection) study and the IMPROVE-IT (IMProved Reduction of
Outcomes: Vytorin Efficacy International Trial) study. This press release is
furnished as Exhibit
99.4 to this 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
Schering-Plough Corporation
| |
|
|
|
|
| |
|
|
| By: |
/s/
Steven H. Koehler |
|
| |
Steven H. Koehler |
|
| |
Vice President and Controller |
|
Date: July 21, 2008